All News
Links:
Half the Experts are Wrong (2.17.2023)
Dr. Jack Cush reviews the news and tries to stump the expert panel this week on the podcast.
Read ArticleGingival Inflammation Parallels Saliva “Cytokine Score”
Researchers at NYU College of Dentistry have developed a single score to describe the level of cytokines in the saliva, and this score is linked with the severity of clinical gum inflammation, according to a study
Read ArticleNew Laboratory Insights for the ANA+ Consult
A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).
Read ArticleDrug Safety Differences with New Novel Therapies in RA
Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particular differences for specific infection or other adverse event risks.
Read ArticleLinks:
Older Lupus Patients Need Follow-Up After Hospital Discharge
Medicare beneficiaries 65 and older with lupus faced dramatically higher mortality when they received no follow-up care during the month after a hospital stay, researchers found.
Read ArticleLinks:
KNOW YOUR NUMBERS! (2.10.2023)
Dr. Jack Cush reviews the news, journal articles and the numbers, from the past week on RheumNow.com.
Read ArticleLinks:
Links:
Without DMARDS, Shoulder Arthroplasty Increasing in Rheumatoid Arthritis
The need for total shoulder arthroplasty (TSA) in rheumatoid arthritis (RA) patients appears to depend on the use of disease modifying antirheumatic drugs (DMARDs), according to Seminars in Arthroplasty.
Read ArticleDoes Methotrexate Increase Skin Cancer Risk?
There are several reports suggesting a link between methotrexate (MTX) use and certain skin cancers, yet these are confounded by a higher risk of skin cancers with inflammatory conditions like rheumatoid arthritis of which MTX is the most common treatment.
Read ArticleLinks:
Deucravacitinib - Effective in Systemic Lupus Erythematosus
A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active systemic lupus erythematosus (SLE).
Read ArticleSerious Infection Risk in Pediatric Psoriasis with Ustekinumab, Etanercept, or Methotrexate
Etanercept was FDA approved for use in pediatric psoriasis (PsO) in 2016 and ustekinumab was similarly approved in 2020. This comparative analysis looks at the risk of serious infections (SIE) requiring hospitalization in pediatric PSO patients treated with ustekinumab, etanercept, or
Read ArticleGRAPPA Recommendations for Treating Enthesitis in Psoriatic Arthritis
GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes.
Read ArticleICYMI: GRAPPA Recommendations for Treating Enthesitis in Psoriatic Arthritis
GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes.
Read ArticleHigh- Versus Low-Dose Exercise Therapy for Knee Osteoarthritis
Exercise is known to improve function, pain and quality of life (QOL) in patients with knee osteoarthritis (KOA), but optimal amount of exercise is unknown.
Read Article